BRNS vs. NKTX, SBTX, URGN, ANL, NBTX, NLTX, AVIR, EPIX, KMDA, and XOMA
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Nkarta (NKTX), Silverback Therapeutics (SBTX), UroGen Pharma (URGN), Adlai Nortye (ANL), Nanobiotix (NBTX), Neoleukin Therapeutics (NLTX), Atea Pharmaceuticals (AVIR), ESSA Pharma (EPIX), Kamada (KMDA), and XOMA (XOMA). These companies are all part of the "pharmaceutical preparations" industry.
Barinthus Biotherapeutics (NASDAQ:BRNS) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Barinthus Biotherapeutics presently has a consensus target price of $8.00, indicating a potential upside of 318.85%. Nkarta has a consensus target price of $17.83, indicating a potential upside of 162.64%. Given Barinthus Biotherapeutics' higher probable upside, research analysts plainly believe Barinthus Biotherapeutics is more favorable than Nkarta.
Nkarta received 42 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 72.73% of users gave Nkarta an outperform vote.
Nkarta's return on equity of -34.13% beat Barinthus Biotherapeutics' return on equity.
In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for Barinthus Biotherapeutics and 2 mentions for Nkarta. Barinthus Biotherapeutics' average media sentiment score of 1.60 beat Nkarta's score of 0.98 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.
Barinthus Biotherapeutics has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 8.7% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Barinthus Biotherapeutics has a beta of -0.45, meaning that its share price is 145% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
Summary
Barinthus Biotherapeutics beats Nkarta on 8 of the 15 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
